Phillyrin alleviates pulmonary fibrosis via modulation of the TGF-β1/Smad and Nrf2/HO-1 signaling pathways
Molecular Immunology · 2026-09 · 197 · 1-12
DOI: 10.1016/j.molimm.2026.06.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Immunology, 2026-09. Verfasst von Yang Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xi'an Jiaotong University, Xi'an, PR China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Transforming Growth Factor beta1, Signal Transduction, Pulmonary Fibrosis. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Shaanxi Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
PURPOSE: Pulmonary fibrosis (PF) is a fatal disease with limited treatment options. This study aimed to investigate the therapeutic potential of phillyrin (Phi), a bioactive compound derived from Forsythia suspensa, in treating PF and to explore its underlying mechanisms. METHODS: A bleomycin (BLM)-induced murine PF model and TGF-β1-stimulated L929 fibroblasts were employed. Histopathological changes, collagen deposition, inflammatory cytokines (IL-1β, TNF-α), oxidative stress markers (MDA, SOD, GSH), and fibrotic proteins (α-SMA, COL1A1, etc.) were evaluated. Key signaling pathways, including Nrf2/HO-1 and TGF-β1/Smad2/3, were analyzed. RESULTS: Phi significantly attenuated BLM-induced lung damage, collagen accumulation, and fibrosis scores (p < 0.001). It suppressed inflammation and oxidative stress by activating the Nrf2/HO-1 pathway. In TGF-β1-stimulated L929 cells, Phi inhibited proliferation, migration, invasion, and extracellular matrix (ECM) deposition. Furthermore, Phi attenuated TGF-β1-induced G2/M phase cell cycle arrest and reduced the levels of key fibrotic proteins. These effects were mediated through suppression of the TGF-β1/Smad2/3 pathway and epithelial-mesenchymal transition (EMT). CONCLUSION: Phi exerts anti-fibrotic, antioxidant, and anti-inflammatory effects by dual modulation of the TGF-β1/Smad2/3 and Nrf2 pathways, demonstrating significant therapeutic potential for pulmonary fibrosis. It is noteworthy that the in vitro evidence comes from L929 fibroblasts, and further validation in lung-relevant cell models would strengthen the translational relevance of these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Xi'an Jiaotong University, Xi'an, PR China.
- Shaanxi Panlong Pharmaceutical Group Limited by Share LTD, Xi'an, PR China.
- School of Pharmacy, Xi'an Jiaotong University, Xi'an, PR China. Electronic address: liwf@mail.xjtu.edu.cn.
- School of Pharmacy, Xi'an Jiaotong University, Xi'an, PR China. Electronic address: niuxf@mail.xjtu.edu.cn.
Förderung
- Shaanxi Administration of Traditional Chinese Medicine
Zitieren
APA
Liu, Y., Liu, L., Song, H., Ma, Y., Luo, Y., Wen, S., Li, L., Xia, S., Zhu, R., Zhang, D., Li, W., & Niu, X. (2026). Phillyrin alleviates pulmonary fibrosis via modulation of the TGF-β1/Smad and Nrf2/HO-1 signaling pathways. Molecular Immunology, 197, 1-12. https://doi.org/10.1016/j.molimm.2026.06.015
Vancouver
Liu Y, Liu L, Song H, Ma Y, Luo Y, Wen S, et al. Phillyrin alleviates pulmonary fibrosis via modulation of the TGF-β1/Smad and Nrf2/HO-1 signaling pathways. Molecular Immunology. 2026;197:1-12. doi:10.1016/j.molimm.2026.06.015
BibTeX
@article{Liu2026,
author = {Liu, Yang and Liu, Lingyi and Song, Huixin and Ma, Yajing and Luo, Yuzhi and Wen, Sha and Li, Lingli and Xia, Songyuan and Zhu, Ruisi and Zhang, Dezhu and Li, Weifeng and Niu, Xiaofeng},
title = {Phillyrin alleviates pulmonary fibrosis via modulation of the TGF-β1/Smad and Nrf2/HO-1 signaling pathways},
journal = {Molecular Immunology},
year = {2026},
volume = {197},
pages = {1--12},
doi = {10.1016/j.molimm.2026.06.015}
}
EUVIMED